Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, allo-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.

This document provides methods and materials involved in identifying and treating mammals (e.g., humans) having membranous nephropathy. For example, methods and materials for determining the likelihood that a mammal (e.g., a human) having membranous nephropathy (e.g., lupus membranous nephropathy) will progress to end stage kidney disease are provided. Methods and materials for treating membranous nephropathy likely to develop end stage kidney disease also are provided.

Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.

The present invention relates to the field of myocardial injury. More specifically, the present invention provides methods and compositions useful in the diagnosis, prognosis and/or assessment of myocardial injury. In a specific embodiment, a method comprises the steps of (a) diagnosing a subject as having myocardial injury based on the statistically significant over expression of one or more markers described herein compared to a baseline value, wherein the markers are measured in a biological sample obtained from the subject; and (b) treating the subject with one or more of an anti-thrombolysis agent, coronary bypass surgery or angioplasty.

An in-vitro method for early diagnosing or prediction of immune-mediated inflammatory diseases, comprising: —obtaining a sample from a subject; —quantifying simultaneously by one LC/MS-MS analysis of said sample, a presence of V65 vitronectin fragment or fragment, variant or degradation product thereof; and a presence of a complement C3f or fragment or variant or degradation products thereof.

The present invention provides compositions and methods for predicting the probability of preterm birth in a pregnant female. The present invention provides a composition comprising one or more biomarkers selected from the group consisting of the biomarkers set forth in FIGS. 1 and 2 and Tables 1 through 3, 6 through 38, and 44 through 68. In one embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, optionally preterm birth associated with preterm premature rupture of membranes (PPROM) or preterm birth associated idiopathic spontaneous labor (PTL), the method comprising measuring in a biological sample obtained from the pregnant female one or biomarkers selected from one or more of the biomarkers set forth in FIGS. 1 and 2 and Tables 1 through 3, 6 through 38, and 44 through 68 to determine the probability for preterm birth in said pregnant female.

A method of stabilising a biological sample including glutathione (GSH) and glutathione disulfide (GSSG), including a) providing the biological sample having GSH and GSSG; b) contacting GSH and GSSG of the sample with a maleimide to obtain maleimide-alkylated GSH; c) separating excess maleimide from maleimide-alkylated GSH and GSSG; d) contacting maleimide-alkylated GSH and GSSG with a reducing agent such as TCEP under conditions which allow reduction of GSSG by the reducing agent such as TCEP to obtain further GSH; and e) contacting maleimide-alkylated GSH and GSH with a heavy isotopologue of the maleimide to obtain a heavy isotopologue of the maleimide-alkylated GSH. A stabilised biological sample is provide containing maleimide-alkylated GSH and a heavy isotopologue thereof, as well as a mass-spectrometric method for quantifying maleimide-alkylated GSH and a heavy isotopologue thereof in a sample and a kit for stabilising a biological sample including GSH and GSSG for mass spectrometric analysis.

A method of detecting a protein by mass spectrometry comprises: providing a solution comprising a dendritic detergent and a protein; providing a mass spectrometer comprising a nanoelectrospray ionisation source, a mass analyser and a detector; vaporising the solution using the nanoelectrospray ionisation source; ionising the protein; resolving the ionised protein using the mass analyser; and detecting the resolved protein using the detector. A method of extracting a membrane protein from its native membrane comprises: providing a membrane protein in its native membrane; contacting the membrane protein with a dendritic detergent. Dendritic detergents for use in the methods are also provided.

The presence of mild electrophiles, such as aldehydes, during the denaturation of glycoproteins or glycopeptides and subsequent enzymatic deglycosylation reduces artifacts in subsequent analyses of the glycans released from the glycoproteins or glycopeptides.

Disclosed herein is a novel p53 complex and a collection of compounds that can tightly associate with p53 to efficiently rescue wildtype p53 structure and function, and the methods of making and using the complex and the compounds, including for diagnosis, prognosis, and treatment of p53 related disorders such as cancer and aging.